Evidence map›Paper›PMID 38528381›Full record

ReviewAllergy, asthma & immunology research2024

Epigenetic Approaches to Identifying Asthma Endotypes.

Audrey Kelly, Paul Lavender

Abstract readReview
In one paragraph

Review in Allergy, asthma & immunology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Flavonoids as potential anti-asthmatic agents.Frontiers in immunology · 2026
    Review
  5. Article
  6. Article
  7. The Effect of Long-Term Exposure to OInternational journal of environmental research and public health · 2025
    Article
  8. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Audrey KellyPeter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King's College London, London, United Kingdom.
Paul LavenderPeter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King's College London, London, United Kingdom. paul.lavender@kcl.ac.uk.ORCID https://orcid.org/0000-0001-8710-0263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of asthma escalated rapidly in the late 20th century. In 2019, the World Health Organization estimated the global number of people affected by the condition to be approximately 260 million, causing 450,000 deaths during that year. While there have been advances in therapeutics with the emergence of biologics targeting T2-high asthma, there is still little clarity on the mechanisms underlying the origins of both the condition and all of its endotypes. Several biomarkers for particular asthma phenotypes have been documented. These are generally identified from transcriptomics and proteomics protocols and tend to be biased to T2-high phenotypes. In this review, we summarize some suggestions that analysis of epigenomes may provide alternative datasets that inform of broader asthma endotypes and might highlight pathways amenable for therapeutic intervention.

Indexed as

Asthmaepigenomephenotypeproteometranscriptome

Identifiers

PMID38528381
PMCPMC10973632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.